<DOC>
	<DOCNO>NCT01393730</DOCNO>
	<brief_summary>The purpose research study determine addition dutasteride regimen abiraterone acetate prednisone improve therapy patient castrate-resistant prostate cancer metastatic disease . This study also help determine side effect study treatment often occur .</brief_summary>
	<brief_title>Abiraterone Acetate Combined With Dutasteride Metastatic Castrate Resistant Prostate Cancer</brief_title>
	<detailed_description>Patients receive abiraterone acetate prednisone orally , daily 2 month ( 2 cycle ) outpatient basis . At start cycle 3 , dutasteride take daily . Patients return clinic Day 14 first 3 cycle routine blood test . Patients come clinic every 12 week CT scan and/or x-ray chest , CT scan MRI abdomen pelvis , bone scan , blood test testosterone specialize blood test .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Diagnosis adenocarcinoma prostate Castrate resistant disease Metastatic disease Normal organ marrow function Subjects partner childbearing potential must willing use adequate method birth control Uncontrolled intercurrent illness Uncontrolled hypertension Active symptomatic viral hepatitis chronic liver disease History pituitary adrenal dysfunction Clinically significant heart disease History different malignancy unless diseasefree least 5 year Known brain metastasis History gastrointestinal disorder Prior therapy abiraterone acetate HIVpositive individual antiretroviral therapy Requirement steroid use great equivalent 5 mg prednisone daily Atrial fibrillation cardiac arrhythmia require therapy Thromboembolism last 6 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>prostate</keyword>
	<keyword>metastatic</keyword>
	<keyword>castrate resistant</keyword>
</DOC>